Opinion|Videos|October 4, 2024
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM
The discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please share some key takeaways/pearls.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Spotlighting the Top 10 FDA Oncology Approvals in 2025
2
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting
3
Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML
4
Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer
5